Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|December 8, 2020
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemiaRichard T Maziarz, Mark Levis, Mrinal M Patnaik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationKeith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
Science Translational Medicine|June 12, 2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemiaYiting Lim, Lukasz Gondek, Li Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaFarhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Blood|April 21, 2023
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaAmy E DeZern, Marianna Zahurak, Heather J Symons, et al.
Haematologica|October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemiaKeith W Pratz, Jason Kaplan, Moshe Levy, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|December 8, 2020
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemiaRichard T Maziarz, Mark Levis, Mrinal M Patnaik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationKeith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
Science Translational Medicine|June 12, 2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemiaYiting Lim, Lukasz Gondek, Li Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaFarhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Blood|April 21, 2023
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaAmy E DeZern, Marianna Zahurak, Heather J Symons, et al.
Haematologica|October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemiaKeith W Pratz, Jason Kaplan, Moshe Levy, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Pageof 10